Condition (MeSH)
Hematemesis
ClinicalTrials.gov lists 12 trials for Hematemesis or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 12 trials are tagged with Hematemesis itself; the rest are tagged with a narrower condition beneath it.
When did Hematemesis trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2020 | 1 |
| 2017 | 1 |
| 2014 | 2 |
| 2012 | 2 |
| 2008 | 1 |
| 2006 | 1 |
| 2004 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hematemesis trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 3 | 4 |
| Phase 4 | 3 |
| Not applicable | 4 |
| Observational | 1 |
How many Hematemesis trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 6 |
| Terminated | 1 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Terlipressinum | 2 |
| erythromycin [Eritex] | 2 |
| Metclopramide | 2 |
| Early intravenous tranexamic acid administration | 1 |
| NaCl 0.9% NS | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hematemesis trials report? (6)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Gastrointestinal Bleeding | 2 | 1 |
| Acute allergic reaction | 1 | 1 |
| Coronavirus | 1 | 1 |
| Hypoxemia | 1 | 1 |
| Melena | 1 | 1 |
Showing 5 of 6 adverse events.
Which publications cover Hematemesis? (17)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Prediction of the need for emergency endoscopic treatment for upper gastrointestinal bleeding and new score model: a retrospective study. | BMC gastroenterology | 2022 | Yes |
| Effect of acute upper gastrointestinal bleeding manifestations at admission on the in-hospital outcomes of liver cirrhosis: hematemesis versus melena without hematemesis. | European journal of gastroenterology & hepatology | 2019 | Yes |
| Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding: a cohort study. | Journal of hepatology | 2012 | Yes |
| Prognostic factors in upper gastrointestinal bleeding. | Digestive diseases and sciences | 1994 | Yes |
| Upper Gastrointestinal Bleeding: Etiologies and Management. | Mayo Clinic proceedings | 2019 | No |
Showing 5 of 17 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, prevalence, rare-disease identity, and sub-conditions in mesh.